Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | TACR2 | P21452 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13858849 | 0.97 | ALDH1A1 (0.74) | ALDH1A1KDM4ESMN1; SMN2POLBFDPS | |
| SCHEMBL3788224 | 0.93 | ALDH1A1 (0.76) | ALDH1A1KDM4ESMN1; SMN2POLBFDPS | |
| SCHEMBL1949645 | 0.93 | ALDH1A1 (0.67) | ALDH1A1KDM4ESMN1; SMN2POLBFDPS | |
| Protocatechualdehyde SCHEMBL5782828 | 0.92 | ALDH1A1 (0.60) | ALDH1A1KDM4ESMN1; SMN2POLBMAPT | |
| SCHEMBL4281305 | 0.91 | ALDH1A1 (0.59) | ALDH1A1KDM4ESMN1; SMN2POLBFDPS | |
| SCHEMBL16295256 | 0.90 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2POLBFDPS | |
| SCHEMBL13850149 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2POLBHPGD | |
| SCHEMBL1949360 | 0.89 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2POLBMAPT | |
| SCHEMBL6131789 | 0.88 | KDM4E (0.60) | ALDH1A1KDM4ESMN1; SMN2TACR2MAPT | |
| SCHEMBL14526126 | 0.88 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105503581-B | A kind of water-soluble nano graphenic surface activating agent and its synthetic method and application | 陕西师范大学 | 2017-07-11 | — | — | CN | claimed |
| CN-105503581-A | Water-soluble nano graphene surfactant, and synthesis method and application thereof | UNIV SHAANXI NORMAL | 2016-04-20 | — | — | CN | claimed |
| CN-105503581-B | A kind of water-soluble nano graphenic surface activating agent and its synthetic method and application | 陕西师范大学 | 2017-07-11 | — | — | CN | disclosed |
| CN-105503581-A | Water-soluble nano graphene surfactant, and synthesis method and application thereof | UNIV SHAANXI NORMAL | 2016-04-20 | — | — | CN | disclosed |
| CN-105503581-A | Water-soluble nano graphene surfactant, and synthesis method and application thereof | UNIV SHAANXI NORMAL | 2016-04-20 | — | — | CN | disclosed |
| US-9212196-B2 | Hypophosphorous acid derivatives having antihyperalgic activity and biological applications thereof | UNIVERSITE PARIS DESCARTES (FR) | 2015-12-15 | — | — | US | disclosed |
| US-20140107078-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | UNIVWESITE D"AUVERGNE (FR) | 2014-04-17 | — | — | US | disclosed |
| WO-2012156931-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | UNIVERSITE PARIS DESCARTES (FR) | 2012-11-22 | — | — | WO | disclosed |
| US-7964628-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-06-21 | — | — | US | disclosed |
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-10-07 | — | — | US | disclosed |
| US-7759387-B2 | Fibrinogen receptor antagonists and their use | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2010-07-20 | — | — | US | disclosed |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | NICHOLAS PIRAMAL INDIA LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-0684948-B1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | DIAGNOSTIKFORSCHUNG INST (DE) | 1997-10-22 | — | — | EP | disclosed |
| US-5674467-A | USED IN NMR DIAGNOSIS, RADIODIAGNOSIS OR RADIOTHERAPY | INSTITUT FUR DIAGNOSTIKFORSCHUNG GMBH (DE) | 1997-10-07 | — | — | US | disclosed |
| EP-0684948-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME. | DIAGNOSTIKFORSCHUNG INST (DE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256161-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS AND THEIR USE | FGB, F13B, F2 | ALDH1A1 2548/4885KDM4E 4730/4885SMN1; SMN2 4690/4885 |
| US-20070021489-A1 | Fibrinogen receptor antagonists and their use | FGB, F13B, F2 | ALDH1A1 2548/4885KDM4E 4730/4885SMN1; SMN2 4690/4885 |
| US-20140107078-A1 | HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF | HCAR3, HRH3, SSTR3 | ALDH1A1 1395/4885KDM4E 3875/4885SMN1; SMN2 2789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.